MCM
UTMD icon

MAI Capital Management’s Utah Medical Products UTMD Stock Holding History

MAI Capital Management’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$124 – 4600
2026
Q1 		$124 Hold
2
– – ﹤0.01% 4719
2025
Q4 		$112 Buy
+2
New +$116 ﹤0.01% 4147

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's UTMD Position: Q2 2026 in Review

MAI Capital Management sold out of Utah Medical Products (UTMD) in Q2 2026, closing a stake of 2 shares — an estimated $124 sold.

MAI Capital Management first reported a position in UTMD in Q4 2025 and held it in 2 quarters. The position peaked at $124 in Q1 2026. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • MAI Capital Management reported no remaining Utah Medical Products position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 2 Utah Medical Products shares in Q2 2026, an estimated $124.
  • MAI Capital Management first reported a position in Utah Medical Products in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Utah Medical Products position peaked at $124 in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.